Compounded pain creams occupy a specific place on every PBM audit worklist: high per-claim reimbursement, a formula that changes ingredient by ingredient, and a documentation trail a pharmacy either has or does not. The HHS Office of Inspector General found that Medicare Part D spending on compounded topical drugs grew 24 times between 2010 and 2016 and flagged roughly 550 pharmacies for questionable billing in 2016 alone. That growth curve is why a pharmacy that cannot document how a cream was formulated, who prescribed it, and why, now faces a different audit than the one it may remember from a decade ago.
The Reimbursement Gap Behind the Audit Wave
The OIG's report found the billing pattern concentrated rather than random: more than a quarter of the flagged pharmacies sat in just four metropolitan areas. CVS Caremark's provider manual now requires a pharmacy to apply for and receive pre-approval as a Complex Compound Provider before submitting non-sterile complex compound claims, and every active and inactive ingredient in a multi-ingredient compound has to carry its own National Drug Code or UPC on the claim; an ingredient that cannot be supported by a compendia listing can subject the claim to chargeback. Medicaid managed-care plans such as Centene and its Envolve Pharmacy Solutions subsidiary run their own pharmacy audits with recoupment and network-termination authority, alongside the commercial PBMs.
USP <795> and the Paperwork Behind Every Formula
Topical pain creams are nonsterile preparations, governed by USP General Chapter <795> rather than the sterile-compounding chapter <797> that applies to injectable and ophthalmic products. USP's compounding standard requires a master formulation record for each unique preparation, documenting the ingredients, quantities, compounding procedure, and equipment used, together with a beyond-use date tied to the preparation's stability. A PBM auditor pulling a compound claim checks whether that record and the matching compounding record exist for the specific fill billed. A pharmacy that compounds from memory, or cannot produce the record a claim was built on, fails that comparison before the audit reaches pricing.
Marketer and Prescriber Relationships Draw Separate Scrutiny
Compounded pain creams also draw attention to the relationships behind the prescription. In April 2026, the HHS Office of Inspector General announced that a former pharmacy president was sentenced to 24 months in federal prison for a health care fraud and kickback scheme built on medically unnecessary compounded scar creams, pain creams, migraine medication, and vitamins, billed through Main Avenue Pharmacy between 2014 and 2016 and totaling $33 million. That scheme fits a structure federal kickback law targets: payment to a marketer based on the volume or value of business generated, rather than for a legitimate service, for creams the patient never asked for and the prescriber never clinically indicated. A pharmacy can carry that exposure even when it did not design the arrangement. A PBM audit that finds compound claims concentrated among a small group of prescribers, or tied to a marketing relationship the pharmacy never fully vetted, treats that concentration as a fraud indicator on its own, and a pattern severe enough can move from a recoupment demand into a network termination.
A pharmacy that cannot produce the master formulation record a claim was built on fails the audit before pricing is ever reached.
What a Compound Claim File Has to Show
Caremark's provider manual caps what a pharmacy may submit as a multi-ingredient compound's cost at no more than the combined average wholesale price of its ingredients plus a nominal professional allowance, then reimburses at the lesser of several further calculations. A pharmacy that cannot itemize what went into a specific cream has no way to show that math was followed. Recoupment demands on compound claims rarely stop at the sampled claims; PBMs apply a sampled error rate to extrapolate a result across the full lookback period. Contesting either the formula or the extrapolated recoupment through an audit appeal takes the master formulation record, the compounding record, the ingredient-level NDC data, and the marketing relationship behind the prescription, all tied to the same claim.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
How Health Law Alliance Can Help
Health Law Alliance's PBM audit defense attorneys represent compounding pharmacies nationwide against audits, recoupment demands, and network-termination actions tied to topical and compounded pain creams. If your pharmacy is facing a compound-claim audit or a related marketing-arrangement inquiry, contact Health Law Alliance's PBM audit defense attorneys for a free, confidential consultation.
